|Trade names||Fluorodopa F18|
|Other names||6-fluoro-L-DOPA, FDOPA|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||214.18 g·mol−1|
|3D model (JSmol)|
The most common side effects are injection site pain.
Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).
The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS. The trial was conducted at one clinical site in the United States.
- Deng WP, Wong KA, Kirk KL (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry. 13 (11): 1135–1140. doi:10.1016/S0957-4166(02)00321-X.
- "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.
- "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. This article incorporates text from this source, which is in the public domain.
- "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. This article incorporates text from this source, which is in the public domain.
- "Fluorodopa F 18". Drug Information Portal. U.S. National Library of Medicine.